XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.22.1

Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021
--- | --- | ---
Astellas Agreement [Member] | Japan [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | $ 116,977 |
Deferred Revenue | 0 |
Total Consideration | 116,977 |
Astellas Agreement [Member] | Japan [Member] | Development Revenue [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 16,630 |
Deferred Revenue | 0 |
Total Consideration | 16,630 |
Astellas Agreement [Member] | Japan [Member] | License Revenue [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 100,347 |
Deferred Revenue | 0 |
Total Consideration | 100,347 |
Astellas Agreement [Member] | Europe [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 894,764 |
Deferred Revenue | 0 |
Total Consideration | 894,764 |
Astellas Agreement [Member] | Europe [Member] | Development Revenue [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 275,789 |
Deferred Revenue | 0 |
Total Consideration | 275,789 |
Astellas Agreement [Member] | Europe [Member] | License Revenue [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 618,975 |
Deferred Revenue | 0 |
Total Consideration | 618,975 |
AstraZeneca Agreements [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Deferred Revenue | 171,238 | $ 171,516
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 1,002,573 |
Deferred Revenue | 171,238 |
Total Consideration | 1,173,811 |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 341,844 |
Deferred Revenue | 0 |
Total Consideration | 341,844 |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 608,938 |
Deferred Revenue | 0 |
Total Consideration | 608,938 |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member] |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |
Cumulative Revenue | 51,791 |
Deferred Revenue | 171,238 |
Total Consideration | $ 223,029 |

X
- Definition The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition. + References No definition available. + Details
Name: | fgen_CashConsiderationReceivedUnderCollaborationAgreement
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date. + References No definition available. + Details
Name: | fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=fgen_ChinaPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |